The Funds investment objective is to generate returns that closely correspond, before fees and expenses, generally to the price and yield performance of the Solactive Genomics v2 Index (the Index). The Index aims to provide exposure to exchange-listed companies that are positioned to benefit from advances in genomic science and biotechnology. A company must derive at least 50% of its revenue, operating income, or assets from genomics and/or biotechnology to be considered for inclusion in the Index.